Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study

Stephen K. Williamson, John Crowley, Robert B Livingston, Geoffrey Weiss

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.

Original languageEnglish (US)
Pages (from-to)81-83
Number of pages3
JournalInvestigational New Drugs
Volume11
Issue number1
DOIs
StatePublished - Feb 1993
Externally publishedYes

Fingerprint

Thioguanine
Small Cell Lung Carcinoma
Population

Keywords

  • 6-thioguanine
  • chemotherapy
  • phase II
  • small cell lung cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study. / Williamson, Stephen K.; Crowley, John; Livingston, Robert B; Weiss, Geoffrey.

In: Investigational New Drugs, Vol. 11, No. 1, 02.1993, p. 81-83.

Research output: Contribution to journalArticle

@article{128ea69858084a5e9299ef5171637acc,
title = "Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study",
abstract = "Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.",
keywords = "6-thioguanine, chemotherapy, phase II, small cell lung cancer",
author = "Williamson, {Stephen K.} and John Crowley and Livingston, {Robert B} and Geoffrey Weiss",
year = "1993",
month = "2",
doi = "10.1007/BF00873917",
language = "English (US)",
volume = "11",
pages = "81--83",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study

AU - Williamson, Stephen K.

AU - Crowley, John

AU - Livingston, Robert B

AU - Weiss, Geoffrey

PY - 1993/2

Y1 - 1993/2

N2 - Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.

AB - Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.

KW - 6-thioguanine

KW - chemotherapy

KW - phase II

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0027300489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027300489&partnerID=8YFLogxK

U2 - 10.1007/BF00873917

DO - 10.1007/BF00873917

M3 - Article

VL - 11

SP - 81

EP - 83

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -